Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Mitchell

Showing results (121-130 of 131) with videos related to

Pageof 14
Sort By:
Oncoimmunology|August 15, 2025
A phase 2 trial of CXCR4 antagonism and PD1 inhibition in metastatic pancreatic adenocarcinoma reveals recruitment of T cells but also immunosuppressive macrophagesKatherine M Bever, Sarah M Shin, Jennifer N Durham, et al.
Cell Metabolism|November 19, 2019
Selective Persulfide Detection Reveals Evolutionarily Conserved Antiaging Effects of S-SulfhydrationJasmina Zivanovic, Emilia Kouroussis, Joshua B Kohl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2026
A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without cobimetinib in previously-treated unresectable biliary tract cancerThatcher Ross Heumann, Jiayun Lu, Hao Wang, et al.
Biorxiv : the Preprint Server for Biology|October 31, 2023
Immune landscape of tertiary lymphoid structures in hepatocellular carcinoma (HCC) treated with neoadjuvant immune checkpoint blockadeDaniel H Shu, Won Jin Ho, Luciane T Kagohara, et al.
Iscience|January 15, 2025
CD137 agonism enhances anti-PD1 induced activation of expanded CD8<sup>+</sup> T cell clones in a neoadjuvant pancreatic cancer clinical trialJanelle M Montagne, Jacob T Mitchell, Joseph A Tandurella, et al.
Nature Communications|February 10, 2026
Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trialAmanda L Huff, S Daniel Haldar, Alexander A Gergis, et al.
Nature Communications|April 15, 2026
Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trialAmanda L Huff, S Daniel Haldar, Alexander A Girgis, et al.
The Journal of Trauma and Acute Care Surgery|April 4, 2023
Moving the needle on time to resuscitation: An EAST prospective multicenter study of vascular access in hypotensive injured patients using trauma video reviewRyan P Dumas, Michael A Vella, Amelia W Maiga, et al.
Nature Immunology|October 25, 2024
Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinomaDaniel H Shu, Won Jin Ho, Luciane T Kagohara, et al.
The Journal of Clinical Investigation|March 17, 2025
Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signaturesChester J Kao, Soren Charmsaz, Stephanie L Alden, et al.
Pageof 14

Showing results (121-130 of 131) with videos related to

Sort By:
Pageof 14
Oncoimmunology|August 15, 2025
A phase 2 trial of CXCR4 antagonism and PD1 inhibition in metastatic pancreatic adenocarcinoma reveals recruitment of T cells but also immunosuppressive macrophagesKatherine M Bever, Sarah M Shin, Jennifer N Durham, et al.
Cell Metabolism|November 19, 2019
Selective Persulfide Detection Reveals Evolutionarily Conserved Antiaging Effects of S-SulfhydrationJasmina Zivanovic, Emilia Kouroussis, Joshua B Kohl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 30, 2026
A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without cobimetinib in previously-treated unresectable biliary tract cancerThatcher Ross Heumann, Jiayun Lu, Hao Wang, et al.
Biorxiv : the Preprint Server for Biology|October 31, 2023
Immune landscape of tertiary lymphoid structures in hepatocellular carcinoma (HCC) treated with neoadjuvant immune checkpoint blockadeDaniel H Shu, Won Jin Ho, Luciane T Kagohara, et al.
Iscience|January 15, 2025
CD137 agonism enhances anti-PD1 induced activation of expanded CD8<sup>+</sup> T cell clones in a neoadjuvant pancreatic cancer clinical trialJanelle M Montagne, Jacob T Mitchell, Joseph A Tandurella, et al.
Nature Communications|February 10, 2026
Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trialAmanda L Huff, S Daniel Haldar, Alexander A Gergis, et al.
Nature Communications|April 15, 2026
Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trialAmanda L Huff, S Daniel Haldar, Alexander A Girgis, et al.
The Journal of Trauma and Acute Care Surgery|April 4, 2023
Moving the needle on time to resuscitation: An EAST prospective multicenter study of vascular access in hypotensive injured patients using trauma video reviewRyan P Dumas, Michael A Vella, Amelia W Maiga, et al.
Nature Immunology|October 25, 2024
Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinomaDaniel H Shu, Won Jin Ho, Luciane T Kagohara, et al.
The Journal of Clinical Investigation|March 17, 2025
Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signaturesChester J Kao, Soren Charmsaz, Stephanie L Alden, et al.
Pageof 14